Industry News

Pharmaceutical Industry News

Roche will invest $750 million to…

August 20th, 2026|Fierce Pharma|

Roche will invest $750 million to double the size of its Genentech unit's manufacturing facility in Hillsboro, Oregon. The new outlay will support the construction of a fill-finish plant that will produce drug-delivery devices, such

Less than a year after the FDA…

August 20th, 2026|Fierce Pharma|

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray Pharma has again hit a wall at the U.S. regulator.

China’s investigator-initiated…

August 20th, 2026|Fierce Pharma|

China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of transparency. AstraZeneca and Daiichi Sankyo's Enhertu earned a win in a phase 3 non-small cell lung cancer trial.

Aurinia Pharmaceuticals has struck…

August 20th, 2026|Fierce Pharma|

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off Teva's proposed generic for its lupus drug, Lupkynis (voclosporin), in the United States until December of 2036. With the

B. Braun Medical—a maker of IV…

August 20th, 2026|Fierce Pharma|

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and Canada spurred by particulate contamination.

Healthcare comms and…

August 20th, 2026|Fierce Pharma|

Healthcare comms and commercialization agency Lucid Group has hired Eric Muller as its new chief executive officer.

Boehringer Ingelheim has continued…

August 20th, 2026|Fierce Pharma|

Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. But the German drugmaker failed to

If at first you don’t succeed in…

August 19th, 2026|Fierce Pharma|

If at first you don’t succeed in gene therapy, then try, try again, is the lesson Ultragenyx likely took home this week, pocketing its first FDA nod in the class a little over a year

Hundreds of thousands of patients…

August 19th, 2026|Fierce Pharma|

Hundreds of thousands of patients with type 2 diabetes could eventually make the switch to a weekly insulin injection and reduce their annual injections by 85% after NICE, the U.K.’s drug cost watchdog, gave Lilly's

Just eight months after it…

August 19th, 2026|Fierce Pharma|

Just eight months after it introduced its Wegovy pill, Novo Nordisk is testing the GLP-1 in smaller doses in the phase 3 OASIS 5 study.

For the first time, SK…

August 19th, 2026|Fierce Pharma|

For the first time, SK Biopharmaceuticals has reached a settlement with a generics manufacturer that has applied for FDA approval of a copycat version of its epilepsy treatment Xcopri, local news outlets report. SK’s deal

The summer of the high-potency…

August 19th, 2026|Fierce Pharma|

The summer of the high-potency active pharmaceutical ingredient expansion continues, as yet another manufacturing specialist makes inroads to boost capacity for sensitive, in-demand drug ingredients.

Jazz’s bispecific antibody…

August 19th, 2026|Fierce Pharma|

Jazz’s bispecific antibody Ziihera has gained an FDA approval for first-line HER2-positive stomach cancer, unlocking another market as the company builds toward a $2 billion-plus peak sales target.

After receiving a checkered…

August 19th, 2026|Fierce Pharma|

After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the FDA’s crosshairs.

When clients start directing more…

August 19th, 2026|Fierce Pharma|

When clients start directing more and agencies start thinking less, it may feel like the relationship has run its course. But starting over isn’t the only way to get fresh thinking.